CHM.AX stock surges 7650% on massive 153,880 share volume spike

Chimeric Therapeutics Limited (CHM.AX) experienced an extraordinary intraday surge on May 1, 2026, with CHM.AX stock jumping 7650% to A$0.155 on the ASX. Trading volume exploded to 153,880 shares, more than double the average daily volume of 62,690. This dramatic spike reflects extreme volatility in the clinical-stage cell therapy company. Chimeric develops CAR-T and CAR-NK therapies targeting oncology, with multiple programs in phase I trials. The biotech sector remains highly speculative, and CHM.AX stock movements warrant careful analysis before any investment consideration.

CHM.AX Stock Price Action and Volume Dynamics

CHM.AX stock opened at A$0.20 and traded between A$0.155 and A$0.20 during the session. The 7650% gain represents a recovery from the previous close of A$0.002, indicating extreme price volatility typical of micro-cap biotech stocks. Volume surged to 153,880 shares, representing 145% above average, signaling intense trading activity.

The 50-day moving average sits at A$0.1883, while the 200-day average stands at A$0.26608. This positioning suggests CHM.AX stock remains well below its 52-week high of A$0.90 but above the year-to-date low of A$0.001. Technical indicators show overbought conditions with RSI at 86.46 and CCI at 146.41, warning of potential pullback risk.

Market Sentiment and Trading Activity

Trading activity in CHM.AX stock reflects speculative interest in early-stage cell therapy development. The company’s market cap stands at approximately A$88,374, making it a micro-cap stock vulnerable to large percentage swings on modest volume changes.

Liquidation pressures appear minimal given zero debt-to-equity ratio and strong cash position relative to market cap. However, negative earnings per share of -A$0.84 and operating cash flow of -A$0.1889 per share highlight the pre-revenue nature of clinical-stage biotech. Track CHM.AX on Meyka for real-time updates on volume trends and price movements.

Chimeric Therapeutics Pipeline and Clinical Progress

Chimeric develops a portfolio of cell therapies targeting solid tumors and hematological malignancies. The core CHM 0201 NK platform is in phase I trials for treating solid tumors and blood cancers. CHM 1101 (CLTX CAR-T) targets MMP2+ glioblastoma in phase I development.

Additional programs include CHM 0301 for blood cancers, CHM 1301 and CHM 2301 (CAR-NK variants) for solid tumors, and CHM 2101 (CDH17 CAR-T) for neuroendocrine and gastrointestinal cancers. The company’s next earnings announcement is scheduled for August 28, 2026. Clinical progress updates will likely drive future CHM.AX stock movements.

Financial Metrics and Risk Assessment

CHM.AX stock trades at a price-to-sales ratio of 0.0248, reflecting minimal revenue generation. The company reported gross profit margin of 74.47% but operating margin of -458.31%, indicating heavy R&D spending. Net profit margin stands at -420.80%, typical for clinical-stage biotech companies.

Meyka AI rates CHM.AX with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The current ratio of 0.694 indicates potential liquidity constraints, requiring careful cash management through clinical trials.

Final Thoughts

CHM.AX’s 7650% intraday surge reflects speculative trading volatility, not business fundamentals. As a clinical-stage biotech with negative cash flow and no revenue, the stock’s value depends entirely on trial success and commercialization. High trading volume indicates speculation rather than institutional confidence. Multiple cell therapy programs offer long-term potential, but near-term performance hinges on clinical progress. The stock remains highly risky and requires careful due diligence and strong risk tolerance before investing.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.